JNJ-10198409 は神経芽腫がん細胞に対し選択的に細胞障害性と細胞増殖抑制性をもつ by FUJITANI, Mayumi et al.
Ⅰ．Introduction
 Neuroblastoma （NB） is thought to derive from 
transformed sympathoadrenal progenitor cells of 
the neural crest. It is the most common pediatric 
extracranial solid tumor and accounts for approximately 
15% of childhood cancer deaths［1］. High-risk NB is 
treated with an aggressive therapy regimen that can 
include chemotherapy, radiation, surgery, bone marrow 
transplantation and immunotherapy. Unfortunately, the 
long-term survival of patients older than 1 year with 
advanced disease is less than 30% due to relapse and 
extensive metastatic disease［1］.
 In an effort to discover novel drugs for NB, we 
screened cells from the bone marrow of high risk NB 
patients that formed spheres in neural stem cell culture 
conditions with a collection of 143 compounds that 
target protein kinases［2］, and identified JNJ-10198409 
as a compound that potently inhibited cell growth. JNJ-
10198409 is a selective PDGFRβ kinase inhibitor that 
also inhibits c-Abl and Src family kinase activity in vitro
［3］. It was developed as an anti-angiogenic compound 
and was subsequently shown to have anti-proliferative 
activity against a variety of human cancer cell lines［3,4］. 
Here, we demonstrate that JNJ-10198409 inhibited the 
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SUMMARY
Neuroblastoma （NB） is a pediatric tumor that develops from primitive neural crest cells that 
normally form the sympathetic nervous system. Patients with advanced disease have a poor long-term 
survival and new therapies are desperately needed. JNJ-10198409 was identified as a potential NB 
therapy in a screen of a kinase-targeted chemical library. Here we examine the effect of JNJ-10198409 
on established NB cell lines （SK-N-AS and IMR 32） and primary NB cell proliferation and cell 
survival in vitro. JNJ-10198409 selectively inhibited NB cell growth in AlamarBlue assays and rapidly 
induced apoptotic cell death without affecting the growth of primary pediatric neural crest-like stem 
cells （SKPs）. Signaling analysis suggested that JNJ-10198409 may function by inhibiting the activity 
of Src family kinases. Future experiments will explore the efficacy of combining JNJ-10198409 with 
current frontline NB chemotherapeutics.
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in vitro survival of NB cells and not normal neural crest-
like pediatric stem cells, and induced apoptosis of cells 
from NB patients at nanomolar concentrations. JNJ-
10198409 may act in these cells through inhibition of 
Src family kinases.
Ⅱ．Materials and Methods
 Chemicals and reagents. JNJ-10198409［6,7-
（dimethoxy-2,4-dihydro-indeno［1,2-c］pyrazol-3-yl）-
（3-fluro-phenyl）-amine］was provided by the Medicinal 
Chemistry platform at OICR （the Ontario Institute for 
Cancer Research）.
 Cell culture. SKPs （FS105） were isolated from 
neonatal foreskin and cultured as previously described
［5,6］following ethics approval by The Hospital for Sick 
Children Research Ethics Board. SKPs were grown 
as spheres in 25 or 75 cm2 flasks in a 37℃, 5% CO2 
incubator and passaged every 7 days using 1 mg/mL 
collagenase. Dissociated cells were replated in serum-
free proliferation media （PM: 2% B-27 supplement 
（Invitrogen）, 40 ng/mL basic fibroblast growth factor 
（bFGF, BD Biosciences）, 20 ng/mL epidermal growth 
factor （EGF, BD Biosciences）, 100 U/mL penicillin/ 
streptomycin in 3 :1 DMEM :  F12 （Invitrogen）） 
containing 50% SKPs conditioned medium. SKPs were 
used between passages 1-5 unless otherwise indicated. 
Neuroblastoma cells （NB88R2, NB12） were isolated 
from patient bone marrow aspirates as previously 
described［7］. These lines were found to be partially 
contaminated with EBV-expressing B-cells （Loen 
Hansford and D.R. Kaplan, submitted）. We therefore 
established an EBV-free MYCN amplified NB line 
（NB153） from a patient tumor. While NB88R2 and 
NB12 are a mixture of NB and B-cells, we found that 
results are comparable among these 3 lines, so we have 
chosen to report the results of all three lines.
 Tumor samples and bone marrow aspirates were 
obtained from consented patients, as approved by The 
Hospital for Sick Children Research Ethics Board. 
Primary NB cells were passaged every 5 to 7 days by 
manual tituration and dissociated cells were replated 
in PM. Cells were used between passages 3-12. 
Established NB cell lines （SK-N-AS IMR 32） were 
cultured in PM. NIH-3T3 cells were cultured in DMEM 
with 10% fetal bovine serum.
 Assessment of JNJ10198409 effect on NB lines 
proliferation. NB cell lines （SK-N-AS and IMR 32） 
were seeded at 3,000 cells per well in 100 µL medium 
in 96-well microplates and allowed to adhere for 24 
hours prior to drug addition. NB153 spheres were 
dissociated into single cells and seeded at 10,000 cell 
per well in 100 µL medium. 
 JNJ10198409 was dissolved in DMSO to obtain a 
50 mM stock solution and serially diluted thereafter for 
a total of 8-point, 3-fold serial dilutions. Drug effect was 
compared with cells optimally proliferating in 0.05% 
DMSO alone, whereas wells filled with media served as 
background. AlamarBlue （10 µL） was added after 72 
hours, and fluorescence intensity was measured after 24 
hours on a PHERAstar microplate reader, equipped with 
a 540 excitation/l590 emission filter.
 Sphere-formation assay. Cells were seeded in 
triplicate in 96-well non-tissue culture-treated plates at 
3,000 cells/well （2,000 cells/well for NB88R2 cells） in 
50 µL of PM＋CM. Compounds were diluted in PM＋
CM to the indicated concentrations and immediately 
added to seeded cells in a volume of 50 µL, bringing 
the final volume to 100 µL. Wells were retreated with 
compound at the indicated concentrations 3 days post-
plating. Cultures were fixed with 4% paraformaldehyle 
（Electron Microscopy Sciences） at day 7 and sphere 
number determined manually. Percentage of control 
sphere number was calculated as （mean sphere number 
for treated wells/mean sphere number of 0.05% DMSO-
treated wells） x100. EC50 curves were generated with 
data from two individual NB cell samples and one SKP 
sample using GraphPad Prism software （GraphPad 
Software, Inc.）.
 AlamarBlueⓇ cell proliferation assay. Cells were 
seeded and treated with the compounds as above. At 
day 6, alamarBlueⓇ was added to 10% and the plates 
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were incubated an additional 24 hours. Fluorescence 
intensity was measured on day 7 with an excitation filter 
of 535nm and an emission filter of 590 nm. EC50 curves 
were generated using GraphPad Prism software.
 Immunostaining.  Three million dissociated 
NB88R2 cells were plated in 75 cm2 flasks in 30 mL 
PM. JNJ-10198409 was added to a final concentration 
of 0.1 µM or 1 µM. After 3 days, spheres were 
collected, deposited on slides by cytospin and stained 
with anti-Ki67 antibody （BD Bioscience, 1 :200） or 
anti-cleaved caspase 3 antibody （Cell Signaling #9661, 
1 :200）. Total Ki67-positive cells, Ki67-negative cells 
with no cleaved caspase 3 or condensed nuclei and 
Ki67-negative, cleaved caspase 3-positive cells with 
condensed or fragmented nuclei were quantified. Cells 
from 6 random fields were quantified using a 40X 
objective.
 Western blotting. NB88R2 cells were dissociated 
and plated in 75 cm2 flasks at 3x106 cells in 30 mL 
PM with 0.1 µM JNJ-10198409, 1 µM JNJ-10198409 
or 0.01% DMSO for 48 hours. Cells were collected, 
washed in cold phosphate-buffered saline, and lysates 
were prepared in NP-40 lysis buffer （20 mM Tris pH 
8.0, 137.5 mM NaCl, 1% NP-40, 20 mM NaF, 0.5 mM 
Na3VO4, 1 mM PMSF, 20 µg/mL aprotinin, 10 µg/mL 
leupeptin）. Equal amounts of protein （25-50 µg） were 
resolved on 10% polyacrylamide gels and subjected 
to immunoblotting with the following antibodies: 
anti-phospho-PLCγ1 （#2821, 1 :1000）, anti-PLCγ1 
（Abcam ab16953, 1 :4000）, anti-phospho-Shc （#2431, 
1 ;1000）, anti-phospho-Akt （#9271, 1 :1000）, anti-
phospho-Src （#2101, 1 :1000）, anti-phospho-Erk 
（#9101, 1 :2000）, anti-cleaved human PARP （Poly 
ADP ribose polymerase） （#9541, 1 :1000） and anti-
p38MAPK （#9212 ,  1 :1000）.  Unless otherwise 
indicated, all antibodies were from Cell Signaling 
Technology. HRP-conjugated goat anti-mouse IgG and 
goat anti-rabbit IgG secondary antibodies were used.
 PDGF stimulation. NIH-3T3 cells were plated in 
10 cm plastic dish. After the cells had reached 80-90% 
confluency, the cell media was replaced with DMEM 
plus 0.5% fetal bovine serum for 24 hours. Serum-
starved cells were pretreated with DMSO or 5 µM JNJ-
10198409 for 30 minutes followed by a 10 minute 
treatment with 100 ng/mL PDGF or vehicle （4 mM 
HCl）. Cells were washed twice with cold PBS, lysed 
in 300 µL NP-40 lysis buffer and immunoblotted as 
described above. One million dissociated NB88R2 cells 
were plated in 25 cm2 flasks in DMEM: F12 with 2% 
B27. After 3 hours, cells were pretreated with DMSO 
or 5 µM JNJ-10198409 for 30 minutes followed by a 
10 minute treatment with 100 ng/mL PDGF, EGF and 
bFGF. NB88R2 cells were washed, lysed and processed 
as described for NIH/3T3 cells.
 Immunoprecipitation. NB88R2 cells were dissociated 
and plated in 75 cm2 flasks at 3x106 cells in 30 mL PM 
with 0.1 µM JNJ-10198409 or 0.01% DMSO for 48 
hours. Treated cells were lysed as above and 250-500 µg 
of protein lysate were incubated with anti-phosphotyrosine 
（4G10, Upstate Biotechnology） or mouse IgG （Santa 
Cruz Biotechnology）. Immune complexes were collected 
with protein A-Sepharose, washed in lysis buffer, subjected 
to SDS-PAGE and immunoblotted with anti-c-Src （Cell 
Signaling #2109）.
Ⅲ．Results
 JNJ-10198409 inhibits neuroblastoma cell 
growth in vitro. Previously, we developed a cell-based 
high-throughput assay to identify novel therapeutic 
agents that are selectively cytotoxic or cytostatic 
against NB cells［8］and utilized this assay to screen a 
collection of 143 kinase inhibitors［2］. From this screen, 
we identified JNJ-10198409 （Figure 1A）, a PDGF 
receptor β tyrosine kinase inhibitor as cytotoxic against 
cells from multiple NB patients. To confirm the effect 
of JNJ-10198409 on NB cell lines and primary NB 
cell （NB153） proliferation, we examined cell growth 
using an alamarBlue assay and obtained EC50 values 
for each cell line （Figure 1B; SK-N-AS: EC50＝20 nM 
IMR32: EC50＝10 nM; NB153: EC50＝92 nM）. We 
then assessed in vitro sphere formation capacity as a 
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combined measurement of cell survival and proliferation 
activity［8］. Sphere-forming cells obtained from the 
bone marrow of two high-risk NB patients （NB12, 
NB88R2） were dissociated, plated in triplicate in 96-
well plates and treated with serial dilutions of JNJ-
10198409. Cells were re-treated with the compound 
on day 3 and sphere number was determined at day 7. 
In addition, we treated normal human pediatric skin-
derived precursor cells （SKPs）. SKPs are a neural 
crest-like stem cell population that can be cultured from 
pediatric dermis and share many properties with primary 
NB sphere-forming cells including self-renewal as 
spheres in vitro and expression of neural crest markers 
as well as differentiation into neural crest lineages. 
However SKPs are non-tumorigenic and thus provide a 
normal non-transformed stem cell population to evaluate 
whether JNJ-10198409 is selectively toxic against 
NB cells. Treatment with JNJ-10198409 had no effect 
on SKPs sphere formation in vitro at any dose tested 
（Figure 1B） but inhibited sphere formation of both NB 
patient cell isolates in a dose-dependent manner. The 
EC50 for sphere formation was 283 nM for NB12 cells 
（95% CI （Confidence Interval） 29.46 to 2729 nM） 
and 68 nM for NB88R2 cells （95% CI 35.51 to 126.7 
nM）. These results demonstrate that JNJ-10198409 
selectively targets the survival and/or proliferation of 
NB cell lines and cells from NB patients in vitro. 
 JNJ-10198409 treatment induces rapid cell death 
via apoptosis. JNJ-10198409 has been reported to have 
anti-proliferative effects on various cancer cell lines in 
vitro. To investigate the mechanism of action of JNJ-
Fig. 1 JNJ-10198409 inhibits NB cell growth at nanomolar concentrations. A, Chemical structure 
of JNJ-10198409. B, JNJ-10198409 inhibits proliferation of NB cell lines SK-N-AS and IMR32 
and a primary NB sphere-forming line NB153. EC50 curves are shown demonstrating the effect 
of JNJ-10198409 on the proliferation of NB cell lines, using AlamarBlue as a read-out. （SK-N-
AS: EC50＝20 nM, IMR32: EC50＝10 nM, NB153: EC50＝92 nM） C, EC50 curves are shown 
demonstrating the effect of JNJ-10198409 on the self-renewal and survival of cells from the bone 
marrow of high risk NB patients as measured in a sphere formation assay. NB cells （NB12 and 
NB88R2） had a dose-dependent decrease in sphere formation with EC50 values in the nanomolar 
range （283 nM for NB12 and 68 nM for NB88R2） while normal pediatric neural crest-like stem 
cells （SKPs, line FS105） were unaffected. Points, mean of 2 independent experiments; Bars, SD.
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Additionally, treatment with 0.1 µM JNJ-10198409 
induced an increase in PARP cleavage after 48 hours, 
supporting apoptosis induction via activation of the 
caspase cascade （Figure 2C）.
 JNJ-10198409 does not act through PDGFRβ 
inhibition in cells from NB patients but inhibits 
Src phosphorylation. JNJ-10198409 was developed 
as a PDGFRβ selective antagonist and both primary 
NB tumors and some established NB cell lines have 
been shown to express PDGFRβ［2］. Therefore we 
asked whether JNJ-10198409 treatment altered PDGF-
dependent signaling in cells from NB patients. We 
first investigated whether PDGF-dependent signaling 
pathways were active in cells from NB patients （Figure 
3A）. Stimulation of NIH-3T3 cells with PDGF resulted 
in rapid phosphorylation of the PDGFR downstream 
targets, PLCγ1, Shc, Akt and Erk1/2 （Figure 3B）. 
Phosphorylation of the downstream targets was 
blocked by a 30 minute pre-incubation with 5 µM 
10198409 in cells from NB patients, NB88R2 cells were 
treated with 0.1 µM, 1 µM JNJ-10198409 or DMSO for 
72 hours. Treated cells were immunostained for markers 
of proliferation （Ki67） and apoptosis （cleaved caspase 
3, nuclear DNA condensation and fragmentation）. Ki67-
positive cells and Ki67-negative cells without cleaved 
caspase 3 staining or condensed nuclei were scored as 
live cells while apoptotic cells were identified as Ki67-
negative, cleaved caspase 3-positive cells or Ki67-
negative cells with condensed or fragmented nuclei 
（Figure 2A）. Under the control conditions, NB88R2 
cells grew robustly as spheres and the majority of cells 
were Ki67-positive or lacked markers of apoptotic 
cell death （Figure 2B）. Low concentrations of JNJ-
10198409 induced rapid apoptosis in NB88R2 cells 
with cleaved caspase 3 and condensed or fragmented 
nuclei observed in 66.2＋6.8% of cells. JNJ-10198409 
treatment induced apoptosis in a dose-dependent manner 
with over 83.7＋9.8% of cells treated with 1 µM JNJ-
10198409 exhibiting markers of apoptosis by 72 hours. 
Fig. 2 JNJ-10198409 induces apoptotic cell death of cells from NB patient’s bone marrow. A, NB88R2 
cells were treated with DMSO, 0.1 µM JNJ-10198409 or 1 µM JNJ-10198409 for 72 hours. Treated 
cells were deposited on slides by cytospin and subjected to immunostaining for Ki67 （red） and 
cleaved caspase 3 （green） with Hoechst 33342-staining of nuclei （blue）. A representative field is 
shown for the indicated treatments. B, Quantification of live and apoptotic cells from 6 random fields 
for each treatment condition as described in Methods. C, NB88R2 cells were treated with 0.1 µM JNJ-
10198409 or DMSO for 48 hours. Immunoblots of JNJ-10198409-treated cell lysates demonstrated 
increased PARP cleavage. Total protein loading was visualized by p38MAPK immunuoblotting.
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library were not identified as NB cell-cytotoxic hits at 
1 µM［2］. Additionally, imatinib that also inhibits c-Kit 
and PDGFR kinase activities, had no effect on NB cell 
sphere formation （K.M.S. and D.R.K., unpublished 
observations）.
 To determine whether JNJ-10198409 inhibits Src 
kinase activity in the cells from NB patients, NB88R2 
cells were treated with DMSO or 0 .1  µM JNJ-
10198409 for 48 hours, and cell lysates were subjected 
to immunoprecipitation with anti-phosphotyrosine 
followed by and lysates probing with anti-c-Src （Figure 
3C）. Decreased c-Src tyrosine phosphorylation was 
evident, suggesting that JNJ-10198409 targets Src 
family kinases in the cells from NB patients. 
JNJ-10198409. In contrast, no significant increase in 
phosphorylation of PLCγ1, Shc, Akt or Erk1/2 was 
observed following stimulation of cells from NB patients 
with PDGF （Figure 3B）. These results suggested that 
PDGFR was not the target of JNJ-10198409 in those 
cells.
 In addition to PDGFRβ and PDGFRα, JNJ-
10198409 inhibits the kinase activity in vitro of c-Abl 
（IC50＝22 nM） and Src family members, c-Src, Lck 
and Fyn （IC50＝100 to 378 nM）［3］. It is unlikely 
that c-Abl inhibition in cells from NB patients is 
responsible for the observed cytotoxic effect, because 
additional c-Abl-selective kinase inhibitors （imatinib 
and nilotinib） present in the kinase-targeted chemical 
Fig. 3 JNJ-10198409 inhibits Src phosphorylation but does not alter PDGFR-dependent 
signal transduction in cells from NB patients. A, Diagram of PDGF-dependent signal 
transduction pathways with selected PDGFR targets and interaction partners indicated. B, 
NB88R2 or NIH-3T3 cells were pretreated with JNJ-10198409 and transient stimulation 
with PDGF as described in Methods. Immunoblots of NB88R2 cell lysates show no 
activation of PDGF-dependent signaling pathways while those for NIH-3T3 demonstrate 
PDGF-dependent stimulation of Shc, Akt, PLCγ and ERK1/2 phosphorylation that is 
blocked by JNJ-10198409 pretreatment of cells. C, JNJ-10198409 treatment decreased 
c-Src phosphorylation in NB88R2 cells. Cells were treated with 0.1 µM JNJ-10198409 
or DMSO for 48 hours, lysed, immunoprecipitated with anti-phosphotyrosine antibodies 
（4G10, top panel） or control IgG （middle panel） and immunoblotted for c-Src. Equal 
volume of input lysate was immunoblotted for c-Src （lower panel）.
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present in the kinase-targeted chemical library were 
not identified as NB cell line hits. These observations 
suggest that c-Abl is also not the target of JNJ-10198409 
in NB cells.
 Of the known targets of JNJ-10198409, Src family 
kinases are the most likely candidates. A dual Src/
c-Abl inhibitor, dasatinib, was reported to inhibit the 
proliferation of NB cell lines［16,17］and reduced tumor 
volume in NB xenograft tumor models［17］. We show 
here that treatment with nanomolar concentrations of 
JNJ-10198409 substantially decreased c-Src tyrosine 
phosphorylation in cells from NB patients, suggesting 
that Src family kinases are the therapeutically relevant 
target of JNJ-10198409.
 Src family kinases are rarely mutated in human 
cancers but their expression or activity is frequently 
increased （reviewed in［18］）. Despite the prevalence of 
Src activation in human cancers, targeted therapy against 
Src family kinases has only recently entered the clinic
［19］. It is possible that JNJ-10198409 can be combined 
with other NB therapeutic agents and future studies will 
explore these combination therapies.
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Ⅳ．Discussion
 In this study, we characterized the effect of JNJ-
10198409 on NB cell lines and primary cells from 
NB patients in vitro. JNJ-10198409, developed as a 
selective PDGFRβ kinase inhibitor, was identified in 
a cell-based screen for NB cell cytotoxic agents from a 
collection of 143 kinase inhibitors［2］. We demonstrated 
that treatment with nanomolar doses of JNJ-10198409 
reduced the survival of NB cells from multiple patients 
and induced apoptotic cell death.
 JNJ-10198409 was developed as an anti-angiogenic 
compound that also possessed modest anti-proliferative 
activity against a number of human cancer cell lines 
in vitro and in vivo［3,4］. JNJ-10198409 is an ATP-
competitive inhibitor of PDGFRβ with an IC50 of 
4.2 nM in in vitro kinase assays［3］. To investigate 
the mechanism of JNJ-10198409 action in cells from 
NB patients, we first examined PDGF-dependent 
signaling. However, we did not observe activation of 
PDGFR downstream targets following transient PDGF 
stimulation. Additional kinase inhibitors present in the 
kinase-targeted chemical library with activity against 
PDGFR （AG 1296, mastinib/AB1010 and SU6668） 
were not identified as cytotoxic agents for cells from NB 
patients. Taken together, this data suggests that PDGFR 
is not the relevant target of JNJ-10198409 in those cells.
 JNJ-10198409 is known to suppress the activities 
of c-Abl and the Src family kinases c-Src, Lck and Fyn 
in vitro［3］, suggesting that these kinases may be the 
relevant targets for this compound. Previous studies 
have demonstrated that imatinib, which inhibits c-Abl, 
c-Kit and PDGFR kinase activities, decreased the 
proliferation of established NB cell lines in vitro［2,9-
12］. However, the imatinib concentration required 
to inhibit NB cell line proliferation was significantly 
greater than that required to inhibit the growth of 
chronic myeloid leukemia cell lines which express 
an activated Abl oncogene［13］. In addition, various 
results were observed among NB xenograft tumor 
models［2,9,11,14］and no response was seen in a Phase 
II trial of refractory or recurrent NB patients［15］. In 
our laboratory, additional c-Abl-selective inhibitors 
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